Novartis AG
Company Snapshot
Company Overview
Novartis AG is a Swiss pharmaceutical company established in 1996 by the merger of Ciba-Geigy and Sandoz. The company actively engages in research and development and has a wide range of products, including innovative pharmaceuticals, generics, oncology drugs, biosimilars, and generics. Its products are available in 130 countries. Novartis AG was ranked fifth in sales among pharmaceutical manufacturers in 2023.
After the Sandoz business was spun off, Novartis began operations as a single global operating segment innovative medicines company on October 3, 2023. This company is now involved in developing, producing, distributing, commercializing, and selling innovative medicines.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Cardiovascular, Renal and Metabolic : Entresto, Leqvio, and Other
- Immunology : Cosentyx, Xolai, Ilaris, and Other
- Neuroscience : Kesimpta, Zolgensma, Mayzent, Aimovig, and Other
- Oncology : Promacta/Revolade, Kisqali, Tafinlar + Mekinist, Tasigna, Jakavi, Pluvicto, Lutathera, Kymriah, Piqray/Vijoice, Scemblix, Votrient, Adakveo, Tabrecta, and other
- Established Brands : Lucentis, Sandostatin, Gilenya, Exforge Group, Galvus Group, Diovan Group, Gleevec/Glivec, Afinitor/Votubia, Contract manufacturing, and Other
Applications/End User Industries
- Cardiovascular
- Immunology
- Neuroscience
- Oncology
- Metabolic
- Renal